Sign in
TerminatedNo phase

Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer

Key facts

Who runs it
The University of Texas Health Science Center at San Antonio
Where
San Antonio, United StatesSee the site
Trial code
Status
Terminated
People taking part
129 people enrolled
Started
22 Jan 2021
Ended
6 Jun 2025
Type of study
Observational, 4 groups
Treatments tested
  • Molecular testing for all participants.
  • Germline Testing
  • Survey
Record updated
14 April 2026
Why it stopped
PI leaving institution

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (8)Hide the full registry criteria

Who can take part

  • Aged 18 years or older
  • Patient with histologically confirmed diagnosis of gastric adenocarcinoma
  • Able to understand English or Spanish (only for the prospective cohort)
  • GEJ adenocarcinoma Type II (within 1 cm above and 2 cm below the GEJ) and Type III (2-5 cm below the GEJ)
  • Hyperplastic polyps

Who cannot take part

  • Clinically AND genetically confirmed diagnosis of well-established hereditary cancer syndrome
  • Gastroesophageal junction (GEJ) adenocarcinoma Type I (1-5 cm above the GEJ) as they are treated as esophageal cancer
  • Other benign or malignant histology types (i.e. leiomyoma, gastrointestinal stroma tumors, fundic gland polyps, etc.)

Where in United States

  • Mays Cancer Center, UT Health San AntonioSan Antonio, United States

About the trial

What the trial wants to find out

This protocol is a single-institution feasibility study to identify the molecular and epidemiological risk factors in the development of gastric cancer in high-risk predominantly Hispanic South Texas population. The study is broken down into two main parts: 1) To identify molecular differences in gastric adenocarcinoma (GAC) between Non-Hispanics and Hispanics, stratified by age, and in benign, pre-malignant, and malignant gastric lesions; and 2) To identify environmental and clinicopathological factors in Hispanics associated with specific molecular changes linked to the development of GAC.

The 4 groups in the trial

  • Retrospective Non-Hispanics

    Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants who are alive will be asked to complete a survey and consent to germline testing.

    Treatment: Molecular testing for all participants., Germline Testing, and Survey

  • Retrospective Hispanic

    Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants who are alive will be asked to complete a survey and consent to germline testing.

    Treatment: Molecular testing for all participants., Germline Testing, and Survey

  • Prospective Non-Hispanic

    Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants will be asked to complete a survey and consent to germline testing.

    Treatment: Molecular testing for all participants., Germline Testing, and Survey

  • Prospective Hispanic

    Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants will be asked to complete a survey and consent to germline testing.

    Treatment: Molecular testing for all participants., Germline Testing, and Survey

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Identification of Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer in High-risk Predominantly Hispanic Population
Record updated
14 April 2026